# EDGAR Filing Document

**Accession Number:** 0001534120
**File Stem:** 0001534120-25-000020
**Filing Date:** 2025-11
**Character Count:** 34520
**Document Hash:** 66832f4dd78ad7c018744bcf086ae467
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001534120-25-000020.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001534120-25-000020

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**EFFECTIVENESS DATE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Avalo Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001534120
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 450705648
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291304
- **FILM NUMBER:** 251456112

**BUSINESS ADDRESS:**
- **STREET 1:** 1500 LIBERTY RIDGE DRIVE
- **STREET 2:** SUITE 321
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** 410-522-8707

**MAIL ADDRESS:**
- **STREET 1:** 1500 LIBERTY RIDGE DRIVE
- **STREET 2:** SUITE 321
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cerecor Inc.
- **DATE OF NAME CHANGE:** 20111102

**As filed with the Securities and Exchange Commission on November 6, 2025**

**Registration Statement No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

_____________________

**FORM S-8** 

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933** 

_____________________

**Avalo Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **45-0705648** |
| (State or other Jurisdiction  | (I.R.S. Employer Identification Number) |
| of Incorporation or Organization) | |

---

---

| |
|:---|
| **1500 Liberty Ridge Drive, Suite 321**<br>**Wayne, Pennsylvania 19087** |
| (Address, including zip code, of registrant's principal executive offices) |

---

**Avalo Therapeutics, Inc. 2025 Inducement Award Plan**

(Full title of the plans)

**Christopher Sullivan, Chief Financial Officer**

**Avalo Therapeutics, Inc.**

**1500 Liberty Ridge Drive, Suite 321**

**Wayne, Pennsylvania 19087**

**(410) 522-8707**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

COPIES TO:

**Andrew J. Gibbons, Esq.**<br>**Wyrick Robbins Yates & Ponton LLP**<br>**4101 Lake Boone Trail, Suite 300**<br>**Raleigh, North Carolina 27607**<br>**(919) 781-4000**<br>

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ❑ | Accelerated filer | ❑ |
| Non-accelerated filer | ☑ | Smaller reporting company | ☑ |
| | | Emerging Growth Company | ❑ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.❑

------

**EXPLANATORY NOTE**

This registration statement registers 1,300,000 shares of common stock, par value $0.001 per share ("Common Stock"), of Avalo Therapeutics, Inc. (the "Registrant") that may be issued and sold under the Avalo Therapeutics, Inc. 2025 Inducement Award Plan (the "Inducement Award Plan").

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

---

| | |
|:---|:---|
| **Item 1.** | **Plan Information.** |

---

Information required by Item 1 is included in documents sent or given by the Registrant to participants in the Inducement Award Plan covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act.

---

| | |
|:---|:---|
| **Item 2.** | **Registrant Information and Employee Plan Annual Information.** |

---

The written statement required by Item 2 is included in documents sent or given by the Registrant to participants in the Inducement Award Plan covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act").

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

---

| | |
|:---|:---|
| **Item 3.** | **Incorporation of Documents by Reference.** |

---

The following documents previously filed by the Registrant with the Securities and Exchange Commission (the "Commission") are incorporated herein by reference:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Registrant's <u>[Annual Report on Form 10-K for the fiscal year ended December 31, 2024](https://www.sec.gov/ix?doc=/Archives/edgar/data/1534120/000162828025013986/avtx-20241231.htm)</u>, filed with the Commission on March 20, 2025, pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Registrant's Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025, June 30, 2025, and September 30, 2025 filed with the Commission on <u>[May 12, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000162828025024436/avtx-20250331.htm)</u>, <u>[Au](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000162828025038575/avtx-20250630.htm)[gust 7, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000162828025038575/avtx-20250630.htm)</u>, and <u>[Novembe](https://www.sec.gov/ix?doc=/Archives/edgar/data/1534120/000153412025000018/avtx-20250930.htm)[r](https://www.sec.gov/ix?doc=/Archives/edgar/data/1534120/000153412025000018/avtx-20250930.htm)[6](https://www.sec.gov/ix?doc=/Archives/edgar/data/1534120/000153412025000018/avtx-20250930.htm)[, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1534120/000153412025000018/avtx-20250930.htm)</u>, respectively, pursuant to Section 13(a) of the Exchange Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Registrant's Current Reports on Form 8-K filed pursuant to Section 13(a) of the Exchange Act on <u>[January 2](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000162828025000005/avtx-20250101.htm)</u>, <u>[January 13](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000162828025001228/avtx-20250113.htm)</u>, <u>[March 26, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000162828025014833/avtx-20250325.htm)</u>, <u>[May 8, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000162828025023442/avtx-20250508.htm)</u>, <u>[June 4, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000162828025029225/avtx-20250604.htm)</u>, <u>[June 5, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000162828025029639/avtx-20250603.htm)</u>, <u>[June 17, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000162828025031818/avtx-20250617.htm)</u>, <u>[June 18, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000162828025032011/avtx-20250617.htm)</u>, <u>[June 20, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000162828025032232/avtx-20250620.htm)</u>, <u>[September 22, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000153412025000005/avtx-20250916.htm)</u>, <u>[Octob](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000153412025000009/avtx-20250929.htm)[er 1](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000153412025000009/avtx-20250929.htm)[, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000153412025000009/avtx-20250929.htm)</u>, <u>[October 10, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000153412025000011/avtx-20251010.htm)</u>, and <u>[October 29, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001534120/000153412025000013/avtx-20251029.htm)</u>; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The description of the Registrant's common stock contained in <u>[Exhibit 4.5](https://www.sec.gov/Archives/edgar/data/1534120/000162828025013986/ex-452024descriptionofregi.htm)</u> to the Registrant's Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 20, 2025, including any amendments or reports filed for the purpose of updating such description.

All documents or portions thereof filed, but not furnished, by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date hereof and prior to the filing of a post-effective amendment that indicates that all securities offered under this Registration Statement have been sold or which deregisters all securities then remaining unsold shall be considered incorporated by reference herein and to be a part hereof from the date the documents are filed. In no event, however, will any of the information, including exhibits, that we disclose under Item 2.02 or Item 7.01 of any report on Form 8-K that has been or may be, from time to time, furnished to the Commission, be incorporated by reference into or otherwise become a part of this Registration Statement.

Any statement contained in a document incorporated or considered incorporated by reference herein shall be deemed to be modified or superseded for purposes hereof to the extent that a statement contained herein (or in any other subsequently filed document that also is or is considered incorporated by reference herein) modifies or supersedes

------

such statement. Any such statement so modified or superseded shall not be considered, except as so modified or superseded, to constitute a part hereof.

---

| | |
|:---|:---|
| **Item 4.** | **Description of Securities.** |

---

Not applicable. The class of securities to be offered is registered under Section 12 of the Exchange Act.

---

| | |
|:---|:---|
| **Item 5.** | **Interests of Named Experts and Counsel** |

---

Not applicable.

---

| | |
|:---|:---|
| **Item 6.** | **Indemnification of Directors and Officers.** |

---

Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against amounts paid and expenses incurred in connection with an action or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal proceeding, if such person had no reasonable cause to believe his or her conduct was unlawful. In the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any matter as to which such person has been adjudged to be liable to the corporation unless and only to the extent that the adjudicating court determines that such indemnification is proper under the circumstances.

The Registrant's Certificate of Incorporation and Bylaws provide that its directors and officers will be indemnified by the Registrant to the fullest extent authorized by the Delaware General Corporation Law. In addition, the Registrant's Certificate of Incorporation provides, as permitted by Section 102(b)(7) of the Delaware General Corporation Law, that its directors will not be liable for monetary damages to the Registrant for breaches of their fiduciary duty as directors, unless they (i) violated their duty of loyalty to the Registrant or its stockholders, (ii) acted, or failed to act, in good faith, (iii) acted with intentional misconduct, (iv) knowingly or intentionally violated the law, (v) authorized unlawful payments of dividends, unlawful stock purchases or unlawful redemptions, or (vi) derived an improper personal benefit from their actions as directors.

The Registrant's Bylaws also permit the Registrant to secure insurance on behalf of any officer, director, employee, or agent for any liability arising out of his or her actions, regardless of whether Delaware General Corporation Law would permit indemnification. The Registrant has purchased a policy of directors' and officers' liability insurance that insures its directors and officers.

In addition, the Registrant has also entered into an indemnification agreement with certain of its directors and officers. The indemnification agreements require the Registrant to indemnify and hold harmless and advance expenses to each indemnitee in respect of acts or omissions occurring prior to the time the indemnitee ceases to be an officer and/or director of the Registrant to the fullest extent permitted by applicable law. The rights provided in the indemnification agreements are in addition to the rights provided in the Registrant's Certificate of Incorporation, Bylaws, and the Delaware General Corporation Law.

---

| | |
|:---|:---|
| **Item 7.** | **Exemption From Registration Claimed.** |

---

Not applicable.

---

| | |
|:---|:---|
| **Item 8.** | **Exhibits.** |

---

The following exhibits are filed as part of this Registration Statement:

------

---

| | |
|:---|:---|
| <br>Exhibit No. | Description |
| 4.1 | <u>[Amended and Restated Certificate of Incorporation of Avalo Therapeutics, Inc. (incorporated by reference to Exhibit 3.1.2 to the Current Report on Form 8-K filed with the Commission on May 17, 2018).](https://www.sec.gov/Archives/edgar/data/1534120/000110465918034094/a18-13783_1ex3d1d2.htm)</u> |
| 4.2 | <u>[Certificate of Amendment to Amended and Restated Certificate of Incorporation of Avalo Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Commission on August 26, 2021).](https://www.sec.gov/Archives/edgar/data/1534120/000162828021017637/ex31_charteramendment-name.htm)</u> |
| 4.3 | <u>[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Avalo Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Commission on July 7, 2022).](https://www.sec.gov/Archives/edgar/data/1534120/000162828022018705/ex-31_certificateofamendme.htm)</u> |
| 4.4 | <u>[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Avalo Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Commission on December 28, 2023).](https://www.sec.gov/Archives/edgar/data/1534120/000162828023042817/ex-31_certificateofamendme.htm)</u> |
| 4.5 | <u>[Avalo Therapeutics, Inc. Fifth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant's Annual Report on Form 10-K filed with the Commission on March 20, 2025).](https://www.sec.gov/Archives/edgar/data/1534120/000162828024013786/ex-32fifthamendedandrestat.htm)</u> |
| 5.1\* | <u>[Opinion of Wyrick Robbins Yates & Ponton LLP.](ex-51sx8wyrickopinionconse.htm)</u> |
| 23.1\* | <u>[Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.](ex-231sx8eyconsent2025indu.htm)</u> |
| 23.2\* | <u>[Consent of Wyrick Robbins Yates & Ponton LLP (included in Exhibit 5.1)](ex-51sx8wyrickopinionconse.htm)</u>. |
| 24.1\* | <u>[Power of Attorney (included on signature page to this Registration Statement on Form S-8).](#i1889d9da7d074eb1b01c23568b3c8657_25)</u> |
| 99.1 | <u>[Avalo Therapeutics, Inc. 2025 Inducement Award Plan. (incorporated by reference to Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q filed with the Commission on November 6, 2025).](https://www.sec.gov/Archives/edgar/data/1534120/000153412025000018/ex-102avtxx2025inducementa.htm)</u> |
| 107\* | <u>[Filing Fee Table.](exfilingfees.htm)</u> |

---

\* Filed herewith.

---

| | |
|:---|:---|
| **Item 9.** | **Undertakings** |

---

(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;1.To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii.To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

*provided*, *however*, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

------

&nbsp;&nbsp;&nbsp;&nbsp;2. That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be this initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;(h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**[THE NEXT PAGE IS THE SIGNATURE PAGE]**

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wayne, State of Pennsylvania, on the 6<sup>th</sup> day of November, 2025.

---

| | |
|:---|:---|
| **AVALO THERAPEUTICS, INC.** | **AVALO THERAPEUTICS, INC.** |
| By: | /s/ Christopher Sullivan |
|  | Christopher Sullivan |
|  | Chief Financial Officer |

---

------

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints Garry A. Neil and Christopher Sullivan, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Capacity** | **Date** |
| /s/ Garry A. Neil, M.D. | Chief Executive Officer and Director | November 6, 2025 |
| **Garry A. Neil, M.D.** | (*Principal Executive Officer*) |  |
| /s/ Christopher Sullivan | Chief Financial Officer | November 6, 2025 |
| **Christopher Sullivan** | (*Principal Financial and Accounting Officer*) |  |
| /s/ Michael Heffernan | Director and Chairman | November 6, 2025 |
| **Michael Heffernan** |  |  |
| /s/ Mitchell Chan | Director | November 6, 2025 |
| **Mitchell Chan** |  |  |
| /s/ Jonathan Goldman, M.D. | Director | November 6, 2025 |
| **Jonathan Goldman, M.D.** |  |  |
| /s/ Rita Jain, M.D. | Director | November 6, 2025 |
| **Rita Jain, M.D.** |  |  |
| /s/ Aaron Kantoff | Director | November 6, 2025 |
| **Aaron Kantoff** |  |  |
| /s/ Gilla Kaplan, Ph.D. | Director | November 6, 2025 |
| **Gilla Kaplan, Ph.D.** |  |  |
| /s/ Kevin Lind | Director | November 6, 2025 |
| **Kevin Lind** |  |  |
| /s/ Samantha Truex | Director | November 6, 2025 |
| **Samantha Truex** |  |  |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? exfilingfees

**Exhibit 107**

**Calculation of Filing Fee Table** 

**Form S-8**

(Form Type)

**Avalo Therapeutics, Inc.** 

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered**<sup>(1)</sup> | **Proposed Maximum Offering Price Per Share**<sup>(2)</sup> | **Maximum Aggregate Offering Price**<sup>(2)</sup> | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Equity | Common Stock, $0.001 par value per share | Rule 457 (c) and <br>Rule 457(h)(1) | 1,300,000 shares | $18.02 | $23419500 | $0.0001381 | $3235 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | 1,300,000 shares |  | $23419500 |  | $3235 |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  | $— |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  |  | $3235 |
| (1) | Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 shall also cover any additional shares of Avalo Therapeutics, Inc.'s common stock, par value $0.001 per share (the "Common Stock"), that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock. | Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 shall also cover any additional shares of Avalo Therapeutics, Inc.'s common stock, par value $0.001 per share (the "Common Stock"), that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock. | Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 shall also cover any additional shares of Avalo Therapeutics, Inc.'s common stock, par value $0.001 per share (the "Common Stock"), that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock. | Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 shall also cover any additional shares of Avalo Therapeutics, Inc.'s common stock, par value $0.001 per share (the "Common Stock"), that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock. | Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 shall also cover any additional shares of Avalo Therapeutics, Inc.'s common stock, par value $0.001 per share (the "Common Stock"), that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock. | Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 shall also cover any additional shares of Avalo Therapeutics, Inc.'s common stock, par value $0.001 per share (the "Common Stock"), that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock. | Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 shall also cover any additional shares of Avalo Therapeutics, Inc.'s common stock, par value $0.001 per share (the "Common Stock"), that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock. | Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 shall also cover any additional shares of Avalo Therapeutics, Inc.'s common stock, par value $0.001 per share (the "Common Stock"), that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock. |
| (2) | Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high and low prices of the Registrant's common stock on the Nasdaq Capital Market on October 31, 2025. | Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high and low prices of the Registrant's common stock on the Nasdaq Capital Market on October 31, 2025. | Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high and low prices of the Registrant's common stock on the Nasdaq Capital Market on October 31, 2025. | Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high and low prices of the Registrant's common stock on the Nasdaq Capital Market on October 31, 2025. | Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high and low prices of the Registrant's common stock on the Nasdaq Capital Market on October 31, 2025. | Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high and low prices of the Registrant's common stock on the Nasdaq Capital Market on October 31, 2025. | Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high and low prices of the Registrant's common stock on the Nasdaq Capital Market on October 31, 2025. | Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high and low prices of the Registrant's common stock on the Nasdaq Capital Market on October 31, 2025. |

---

## Exhibit 5.1

**Exhibit 5.1**

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607-7506

November 6, 2025

Avalo Therapeutics, Inc.

1500 Liberty Ridge Drive, Suite 321

Wayne, Pennsylvania 19087

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 filed on or about the date hereof by Avalo Therapeutics, Inc., a Delaware corporation (the "Registrant"), with the Securities and Exchange Commission (the "Registration Statement"), in connection with the registration under the Securities Act of 1933, as amended, of 1,300,000 shares of the Registrant's common stock, par value $0.001 per share (the "Shares"), to be issued pursuant to the Registrant's 2025 Inducement Award Plan (the "Inducement Award Plan"). In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity with the original of all documents submitted to us as copies thereof. As the Registrant's legal counsel, we have examined the proceedings taken, and are familiar with the proceedings proposed to be taken, in connection with the sale of the Shares pursuant to the Inducement Award Plan.

It is our opinion that, upon completion of the proceedings being taken or contemplated by us, as the Registrant's counsel, to be taken prior to the issuance of the Shares, the Shares, when issued in the manner referred to in the Registration Statement and in accordance with the Inducement Award Plan, will be validly issued, fully paid and nonassessable.

This opinion is intended for use in connection with sale of the Shares in accordance with the Plan and is not to be relied upon for any other purpose. Our opinion set forth above is limited to the laws of the State of Delaware, and we do not express any opinion herein concerning any other laws.

This opinion is rendered as of the date first written above and based solely on our understanding of facts in existence as of such date after the aforementioned examination. We assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that may hereafter be brought to our attention whether or not such occurrence would affect or modify any of the opinions expressed herein.

We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to the use of our name wherever appearing in the Registration Statement, including any prospectus constituting a part thereof, and any amendments thereto. In giving this consent, we do not hereby admit that this firm is within the category of persons whose consent is required under Section 7 of the Securities Exchange Act of 1933, as amended, or the rules and regulations promulgated thereunder by the Securities and Exchange Commission.

---

| |
|:---|
| Sincerely, |
| /s/ WYRICK ROBBINS YATES & PONTON LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Avalo Therapeutics, Inc. 2025 Inducement Award Plan of our report dated March 20, 2025, with respect to the consolidated financial statements of Avalo Therapeutics, Inc. and subsidiaries included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Jericho, New York

November 6, 2025

<br>